<code id='802B2C75BA'></code><style id='802B2C75BA'></style>
    • <acronym id='802B2C75BA'></acronym>
      <center id='802B2C75BA'><center id='802B2C75BA'><tfoot id='802B2C75BA'></tfoot></center><abbr id='802B2C75BA'><dir id='802B2C75BA'><tfoot id='802B2C75BA'></tfoot><noframes id='802B2C75BA'>

    • <optgroup id='802B2C75BA'><strike id='802B2C75BA'><sup id='802B2C75BA'></sup></strike><code id='802B2C75BA'></code></optgroup>
        1. <b id='802B2C75BA'><label id='802B2C75BA'><select id='802B2C75BA'><dt id='802B2C75BA'><span id='802B2C75BA'></span></dt></select></label></b><u id='802B2C75BA'></u>
          <i id='802B2C75BA'><strike id='802B2C75BA'><tt id='802B2C75BA'><pre id='802B2C75BA'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:fashion    Page View:159
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In